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Search for the truth is the noblest
occupation of man; its publication is a
duty. —Madame de Stael (1766–1817)
Formats for reporting results from
randomized clinical trials in peer-re-
viewed journals have remained virtually
unchanged and unchallenged for the
past 50 years [1]. However, a number of
developments, some technological and
some political, provide exciting oppor-
tunities to question whether we are
using the most efﬁcient and effective
methods of publication. Here, I suggest
how methods of reporting clinical trials
could be improved and consider the
implications for trial sponsors and
medical journals.
Why Do We Publish Clinical Trial
Results?
Publication (and non-publication) of trial
results can be motivated by several
factors. Research reports may affect
clinical practice, inform patients, inﬂu-
ence future research, and prevent dupli-
cation of effort. Many believe there is a
moral obligation to report results of all
trials that involve patients [2].
Publication also has important secon-
dary effects. These may explain existing
patterns of publication and resistance to
change—despite evidence that current
systems are not the best. Authorship of
papers in journals can establish reputa-
tions and enhance career prospects.
Institutional or corporate reputations
may also beneﬁt. The productivity of
academic departments is judged on their
publication output, which also affects
their chances of obtaining future fund-
ing. The peer-reviewed (and indexed)
journal has thus become part of the
process of academic appointments and
promotions, which, in turn, has spawned
the discipline of bibliometrics [3]. And,
of course, there are ﬁnancial interests:
drug companies use publications to
increase sales while publishers make
money both directly from journal sales
and from spin-offs such as reprints and
advertising [4].
Problems with Existing Publishing
Models
The traditional system of publishing trials
in medical journals reﬂects many of the
limitations of paper-based systems despite
the advent of electronic publishing. In
general, new media and the Internet have
been used to modify existing systems
rather than for dramatic redesign of the
architecture of the medical evidence base.
For example, papers may now be accessed
from journal Web sites but the format of
research articles and the ways in which
ﬁndings are presented remain the same.
While some journals allow additional
material to be displayed electronically,
most still impose strict size limits on
research reports and simply use Web sites
asameansofaccessingdocumentsthatare
identical to the print version. The result is
that, while there have been some major
changes such as the development of ‘‘open
access’’ journals, information remains
hard (or expensive) to access, scattered
across many places, and difﬁcult to syn-
thesize. Producing and disseminating
printed material can be slow, and journal
peer-review often contributes further de-
lays [5].
Another problem with the existing
system is that non-publication of negative
trials and non-reporting of negative out-
comes, coupled with redundant publica-
tion of positive ﬁndings, has led to
systematic publication bias, which can
undermine the reliability of medical
evidence [2,6,7].
Benefits of Alternative Models
One of the most important initiatives
aimed at reducing publication bias is trial
registration (i.e., making details of study
designs publicly available at the start of a
study) [8]. One potential advantage of
electronic publication coupled with trial
registration is that study results can be
linked to the original protocol, or at least
to a summary of its main features. Clear
study identiﬁcation, e.g., by including a
trial register number, should highlight
redundant publications. Secondary anal-
yses will be easy to identify, and the risk of
inadvertently including the same results
more than once (which can bias system-
atic reviews and meta-analyses) will thus
be reduced [6]. Reviewer (and reader)
access to information about trial designs
and planned outcomes, which was re-
corded at the start of each trial, will
permit detection of selective reporting
since reports of results can be compared
with the original protocol [9,10].
Suppression of unfavourable ﬁndings
will be apparent if all studies are regis-
tered at inception. But trial registration
can prevent publication bias only if it is
coupled with a commitment to make
results from all studies available and a
mechanism for implementing and polic-
ing this. Guidelines for pharmaceutical
companies [11] and investigators [12]
have long emphasized the importance
(and some would argue moral obligation)
of publishing results from all studies,
regardless of their outcome. But if such
guidelines are to be enforced, we need a
clear deﬁnition of what is meant by
publication.
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In the era when print technology was
dominant, publication was easy to deﬁne.
The need for expensive equipment and
expertise restricted entry into large-scale
publishing activities. This was the golden
age of the publisher. Within science and
medicine, peer review also became estab-
lished (despite limited evidence of its
effectiveness and lack of agreement about
its primary purpose) [13]. Until recently,
publication therefore meant being
printed in a peer-reviewed journal. How-
ever, a combination of new technology
and increasing public calls for transpar-
ency means that different modes of
publication are now being explored. A
comparison of some publication methods
is shown in Table 1.
Results posting on Web sites.
Following legal action against
companies accused of suppressing
unfavourable ﬁndings, several phar-
maceutical companies have an-
nounced plans to make study ﬁndings
available via Web sites [14,15]. The
American industry association PhRMA
(the Pharmaceutical Research and
Manufacturers of America) has
created a Web site for this purpose
(http://www.clinicalstudyresults.org).
The World Health Organization
(WHO), which has been coordinating
discussion about trial registries, has also
discussed guidelines for the posting of
results. An initial working group
suggested that the summary format
used for regulatory reports might be
used for posting results [16]. (This
summary is sometimes termed ICH E3,
referring to the recommendations of
the International Conference on
Harmonisation, which sets reporting
standards.) This format is now used by
several companies on their Web sites,
although critics point out that it has not
been tested and no guidelines exist
about the amount of detail that should
be provided under each heading [17].
However, since most journals will not
publish material that has already been
published elsewhere, some companies
have stated that results summaries will
not be posted if the trial is pending
publication in a peer-reviewed journal
[18]. Journals have always accepted that
publication of conference abstracts
would not jeopardize subsequent full
publication; however, summaries
posted by Eli Lilly and Glaxo-
SmithKline range from three to 20
pages, and therefore contain
considerably more detail than
abstracts, so the debate continues
about whether journal editors should
consider such postings to be ‘‘full’’
publications [19]. It is ironic that
medical journals, for so long the
bastion of publishing research
ﬁndings, may now prevent or delay
other, possibly better, forms of
publication.
The role of peer-review and
traditional journals. Publication in
peer-reviewed journals has, until now,
been the main mechanism for
disseminating ﬁndings to clinicians
and researchers. Yet the evidence that
peer review in medical journals acts as
an effective measure of quality control
is, at best, extremely limited [13].
Although they have not been through
journal peer review, trial summaries
prepared for regulatory reports are
usually subjected to stringent quality
control mechanisms and are scru-
tinised by both company personnel
and external investigators. It could be
argued that these processes are at least
as good as traditional peer review, but
others will argue that self-regulation by
the industry is never sufﬁcient.
Despite the fact that traditional
papers are considered by many to be
the ‘‘gold standard’’ for clinical trial
publication, their effectiveness in
conveying information has rarely
been tested [1], they fail to provide
enough detail for some users [19], and
selective reporting of outcomes is
common [10].
The standards for reporting
randomized trials in journals have
been raised by guidelines such as the
CONSORT statement [20], yet there is
Table 1. Comparison of Various Methods of Results Publication
Format Length Public
Accessibility
Designed to
Be Read by
Detail of
Study Design
Standard
Format
Guidelines/Evidence
for Contents
Review Process
Conference
abstract
250–500
words
Variable Specialists (clinicians
and researchers)
Low Usually
(IMRAD structure)
No External review (accept/reject)
but no chance to revise
ICH E3 summary
a 2–3,000
words
Only if posted
by company
Regulators Low Yes Weak Extensive internal and some
external (investigators)
Summary posted
oncompany Web
site
b
Variable
a
(4–25 pages)
Yes Public Moderate No
(unless ICH E3)
No Internal
Traditional
journal article
2,500–5,000
words
Depends on
journal policy
Journal
readers
Moderate IMRAD Depends on journal
and if CONSORT is
enforced
Traditional
peer-review
CONSORT-
based article
c
4,000–7,000
words
Yes for open
access journals
Journal/site
users
High Yes Strong
(CONSORT)
Traditional
peer-review
ICH E3 full report
a
(main text)
20–50,000
words
No Regulators High Yes Yes (but not
evidence-based)
Extensive internal and some
external (investigators)
ICH E3 report
a
and fulllistings
Huge (hundreds
of pages)
No Regulators High Yes Yes (but not
evidence-based)
Extensive internal and some
external (investigators)
Databank Unlimited Yes Specialists
(researchers)
High Yes No Post-publication
aFormat proposed by the International Conference on Harmonization E3 guidelines for preparing clinical trial reports for regulatory authorities.
bGSK usually 4–5 pages (1,500–2,000 words); Eli Lilly usually 10–25 pages.
cBased on PLoS Clinical Trials.
DOI: 10.1371/journal.pctr.0010031.t001
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provement [21,22]. In particular,
statistical errors continue to be a
problem [23]. In considering the
merits of various forms of publication,
it would be interesting to compare
journal articles with ICH E3 study
reports in terms of their completeness,
compliance with CONSORT, and
quality of statistical analyses. It would
also be interesting to compare peer
review as performed by journals with
the quality-control mechanisms used by
companies when preparing reports—
for example, in terms of their ability to
detect errors.
Journal articles using the traditional
IMRAD format (i.e., Introduction,
Methods, Results, And Discussion)
combine objective study ﬁndings with
subjective interpretation. While
evidence of many other supposed
beneﬁts of peer review is weak, its
ability to ‘‘tone down’’ conclusions
and remove unfounded claims has
been clearly shown [13]. But peer-
review has a poor record in detecting
incorrect or fabricated data [5]. If the
functions of reporting results and
discussing their implications are
separated, one might argue that peer
review is more helpful for the latter
than the former. A new model might
therefore be for investigators or
sponsors to make results available on
publicly accessible Web sites using
standard templates and for journals to
add value by publishing peer-reviewed
commentary and synthesis.
This model might also help resolve
the ethical arguments about access to
research. Funders, researchers, and
readers increasingly demand access to
clinical trial results for free, yet
producing peer-reviewed journals is a
costly business [24]. If results were
freely accessibly from publicly funded
Web sites, then the costs and delays
involved with peer review would not
affect the primary dissemination of
results. Publishers and editors could
justify journal access charges by
producing lively and informative
reviews and critiques of the latest
ﬁndings. Journals (or electronic
media) could also specialize in
providing information and inter-
pretation for different audiences, for
example, to meet the different needs of
researchers, clinicians, and patients.
Looking Further into the Future
While free text may serve readers well, it
i sn o ta ne f ﬁ c i e n te l e c t r o n i cs t o r a g e
medium. The most powerful, and some
would argue the most efﬁcient and trans-
parent, method of making results avail-
able would be to provide raw (but
anonymized) datasets for public scrutiny.
It is now technically possible to store
results in a computable databank as in the
Trial Bank Project (http://rctbank.ucsf.
edu/). Based on such research, a Global
Trial Bank has recently been established
and aims to be ‘‘the most advanced
computable repository of trial protocol
and results information to promote bio-
medical discovery as well as transparency
and accountability in clinical trial re-
search’’ [16]. Companies already provide
such data to the US Food and Drug
Administration, proving that this is tech-
nically possible and that standard data
transfer protocols are available.
However, adoption of such an initiative
requires not only technical feasibility but
also political and commercial acceptabil-
ity. Individuals, academic institutions,
and commercial companies usually con-
sider data as a precious possession, not
something to be shared with potential
rivals. Many researchers are concerned
that public access to raw data could
encourage inappropriate analyses and
misinterpretation. However, Senn has
suggested that providing computable data
might become ‘‘the ultimate test and
promoter of statistical quality’’ [25]. He
argues that ‘‘every statistician will have to
prepare reports knowing that they will be
scrutinised in the ﬁnest detail by a
frequently hostile posterity’’. This, surely,
is the ultimate form of peer review.
However, although databanks offer excit-
ing possibilities, researchers’ reluctance
to expose their raw data to the world may
hold back change.
Problems Ahead
Publicly accessible, searchable electronic
results dissemination coupled with trial
registers could solve many of the prob-
lems that limit the current system of
research reporting via peer-reviewed
journals. However, such a new system
could also create problems of its own.
For a start, trial registers and publica-
tion vehicles need to be funded. Cur-
rently, some registers and Web sites
charge an administration fee for entries.
This may be a barrier for unfunded
research and projects from the develop-
ing world. It is therefore vital that
sustainable funding systems are devised,
and these must allow inclusive policies for
trial registration and results dissemina-
tion.
Researchers will need to be equipped
to produce reports or data in the re-
quired format. This might be facilitated
by open-access software and protocols for
data transfer, but human effort will also
be required for education and support.
The proposed system of posting results
is largely self-policing and relies to a
greater extent on internal systems of
quality control (within companies or
academic institutions) than traditional
peer-reviewed publication. Performing
trials and handling data according to
Good Clinical Practice requires consid-
erable expertise and resources. This is
currently reinforced by oversight from
regulatory bodies (e.g., random audits) in
the case of the pharmaceutical industry.
The new model of publication might
require similar policing systems, espe-
cially for non-industry-funded studies,
and such systems would require consid-
erable resources.
Box 1. Reporting Results from
Clinical Trials
What’s the problem?
 Clinical trial results are scattered and often
difficult to access.
 Non-publication of unfavourable trials or
negative results causes systematic
publication bias.
 Standard journal articles often omit
important details.
 Traditional peer-review and journal
publishing delays the publication of
findings.
 Enforcing commitments to publish all
results are hampered by a lack of a clear
definition of publication.
What are the opportunities?
 Trial registers/linking protocols with
publications.
 Online publication on Web sites with
minimal running costs.
 Data banks are a possibility for the future.
What’s the solution?
 If all trials were registered at inception,
redundant publication would be easy to
spot and non-publication could be
challenged.
 Links between trial protocols (or registers)
and results would highlight selective
reporting and post hoc analyses.
 Electronic templates for results reporting
should raise standards and improve
searchability.
 Results could be posted on publicly
accessible Web sites at minimal cost.
 Peer-reviewed journals should concentrate
on interpretation, synthesis, commentary,
and discussion.
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cerned about what will happen to their
journals if they are no longer the primary
vehicle for publishing clinical trial results.
Some medical editors have already con-
sidered and even prophesied this scenario
[26–28]. Under the new system, successful
journals will be those brave enough to
focus on other functions. These could
include secondary publications providing
synthesis, commentary, opinion, and in-
terpretation, along with other roles such
as stimulating debate, campaigning for
change, educating, and even entertaining
their readers [26]. Freed from the respon-
sibility of publishing clinical trial results,
journals might also develop new and
more effective models of peer review.
The current system of academic credits
and research assessment based on author-
ship of peer-reviewed articles would need
to be changed. Entries on trial registers
and results databases are currently anon-
ymous. If electronic posting becomes the
primary (or, for some studies, the sole)
method of publication, a fair and trans-
parent system for acknowledging contrib-
utors will need to be devised. This should
be viewed as an opportunity to replace
traditional journal authorship systems,
which are open to abuse [29]. Better
methods of assessing academic perform-
ance than relying on journal impact
factors should also be developed [30].
Use of study identiﬁers presents possibil-
ities to develop more accurate citation
measures relating to the original study
rather than its publication in a journal—
for example, by measuring the number of
times that a study is re-analysed, synthe-
sized, or referred to in journals.
Conclusions
We are at the threshold of a new era of
reporting clinical trial results. We need to
develop an evidence-based system to
ensure that data storage and dissemina-
tion technology are harnessed to produce
the best outcome for all users. Given the
huge sums spent on medical research, it is
a scandal that we have invested so little in
determining the most effective and efﬁ-
cient ways of disseminating ﬁndings. I
urge funders, especially non-commercial
ones such as the Wellcome Trust, Medical
Research Council (in the UK), and Na-
tional Institutes for Health (in the US), to
rise to this challenge. We also need to
consider the best funding models for such
systems that would optimize access to
ﬁndings without creating barriers to non-
commercially funded research. Changes
in research reporting systems will have
implications for the future of medical
journals and for current systems of
measuring research productivity. Given
the established position of peer-reviewed
journals, there is likely to be a gradual
transition from the current model. This
transition may be accelerated by inﬂu-
encers such as journal editors (if they are
brave enough to embrace the change
rather than resisting it), regulators, and
legislators. With wide consultation and
cooperation from all key players (includ-
ing clinicians, drug companies, and bio-
informatics experts), we could produce a
system that greatly enhances the efﬁ-
ciency, transparency, and power of the
medical knowledge base. This is an
opportunity we must not miss. n
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